Garrison Bradford & Associates Inc. increased its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 1.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 73,850 shares of the biopharmaceutical company’s stock after buying an additional 1,300 shares during the period. ACADIA Pharmaceuticals accounts for about 1.8% of Garrison Bradford & Associates Inc.’s holdings, making the stock its 14th largest position. Garrison Bradford & Associates Inc. owned about 0.06% of ACADIA Pharmaceuticals worth $2,060,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Envestnet Asset Management Inc. increased its stake in shares of ACADIA Pharmaceuticals by 23.0% in the first quarter. Envestnet Asset Management Inc. now owns 3,296 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 617 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in shares of ACADIA Pharmaceuticals by 138.8% in the first quarter. PNC Financial Services Group Inc. now owns 4,384 shares of the biopharmaceutical company’s stock valued at $150,000 after buying an additional 2,548 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of ACADIA Pharmaceuticals by 12.8% in the first quarter. Nisa Investment Advisors LLC now owns 4,510 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 510 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at about $161,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of ACADIA Pharmaceuticals during the first quarter valued at about $209,000. Institutional investors and hedge funds own 97.82% of the company’s stock.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ ACAD) opened at 30.94 on Tuesday. The firm’s market cap is $3.79 billion. ACADIA Pharmaceuticals Inc. has a 1-year low of $20.68 and a 1-year high of $40.83. The firm’s 50-day moving average is $29.85 and its 200-day moving average is $31.96.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.17. The company had revenue of $30.50 million for the quarter, compared to analyst estimates of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. ACADIA Pharmaceuticals’s quarterly revenue was up 30400.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.63) EPS. On average, analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.55) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “ACADIA Pharmaceuticals Inc. (ACAD) Shares Bought by Garrison Bradford & Associates Inc.” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/08/22/acadia-pharmaceuticals-inc-acad-shares-bought-by-garrison-bradford-associates-inc.html.

Several equities research analysts have recently issued reports on the stock. ValuEngine upgraded shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, August 10th. Cowen and Company restated an “outperform” rating and issued a $46.00 price objective (up previously from $42.00) on shares of ACADIA Pharmaceuticals in a research note on Thursday, August 10th. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $34.00 price objective on the stock in a research note on Friday, August 11th. Finally, Piper Jaffray Companies set a $54.00 price objective on shares of ACADIA Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $43.23.

In other news, EVP Glenn Baity sold 14,322 shares of the stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $34.88, for a total transaction of $499,551.36. Following the sale, the executive vice president now directly owns 78,578 shares of the company’s stock, valued at approximately $2,740,800.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 54,322 shares of company stock worth $1,699,551. 22.25% of the stock is currently owned by insiders.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Stock Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.